Skip to main content
Top
Published in: Breast Cancer 2/2017

01-03-2017 | Original Article

A unique hypofractionated radiotherapy schedule with 51.3 Gy in 18 fractions three times per week for early breast cancer: outcomes including local control, acute and late skin toxicity

Authors: Kouloulias Vassilis, Gogalis Ioannis, Zygogianni Anna, Armpilia Christina, Antypas Christos, Kokakis John, Koromperlis Porfyrios, Gennimata Vassiliki, Kouvaris John

Published in: Breast Cancer | Issue 2/2017

Login to get access

Abstract

Aim

Evaluation of local control and acute and late toxicity regarding a hypofractionated RT schedule for breast cancer patients.

Methods and Materials

Between October 2007 and October 2009, 80 women with early breast cancer were treated by 42.75 Gy in 15 fractions over 5 weeks. This treatment involved three fractions per week (Monday–Wednesday–Friday). All patients received an additional boost dose to the tumor bed of 8.55 Gy in 3 fractions using 6 MV photons. The primary endpoint included any local recurrence in the treated breast. Secondary endpoint included acute and late radiation skin toxicity. The median follow-up time was 63 months (range 60–72). Radiation toxicity was graded according the RTOG/EORTC criteria.

Results

Neither local nor distant recurrence was noted in any patient during this 3-year follow-up. Grade 0, 1, 2 acute skin toxicity was observed in 56/80 (70.0 %), in 19/80 (23.8 %) and in 5/80 (6.3 %), respectively. Three months post-RT, toxicity grades 0, 1, 2 skin toxicity were 64/80 (80 %), 14/80 (17.5 %) and 2/80 (2.5 %), respectively. Late toxicity as grade 0, 1 was observed in 72/80 (90.0 %) and in 8/80 (10.0 %), respectively, 6 months post-RT, whereas after 1 year they were 78/80 (97.5 %) and 2/80 (2.5 %), respectively.

Conclusions

Preliminary results regarding skin reactions, cosmetic appearance and local control are consistent with published data that support the use of shorter fractionation schedules in early breast cancer patients after breast conservative surgery. Longer follow-up and a randomized prospective study stand in need for the extraction of safe conclusions.
Literature
1.
go back to reference Williams MV, Denekamp J, Fowler JF. A review of alpha/beta ratios for experimental tumours: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys. 1985;11:87–96.CrossRefPubMed Williams MV, Denekamp J, Fowler JF. A review of alpha/beta ratios for experimental tumours: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys. 1985;11:87–96.CrossRefPubMed
2.
go back to reference Rosenstein BS, Lymberis SC, Formenti SC. Biologic comparison of partial breast irradiation protocols. Int J Radiat Oncol Biol Phys. 2004;60:1394–404.CrossRef Rosenstein BS, Lymberis SC, Formenti SC. Biologic comparison of partial breast irradiation protocols. Int J Radiat Oncol Biol Phys. 2004;60:1394–404.CrossRef
3.
4.
go back to reference Jones B, Dale RG, Deehan K, Hopkins KI, Morgan DAL. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol. 2001;13:71–81. Jones B, Dale RG, Deehan K, Hopkins KI, Morgan DAL. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol. 2001;13:71–81.
5.
go back to reference Yamada Y, Ackerman I, Franssen E, MacKenzie RG, Thomas G. Does the dose fractionation schedule influence local control of adjuvant radiotherapy for early stage breast cancer? Int J Radiat Oncol Biol Phys. 1999;44:99–104.CrossRefPubMed Yamada Y, Ackerman I, Franssen E, MacKenzie RG, Thomas G. Does the dose fractionation schedule influence local control of adjuvant radiotherapy for early stage breast cancer? Int J Radiat Oncol Biol Phys. 1999;44:99–104.CrossRefPubMed
6.
go back to reference Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomized trial. Radiother Oncol. 2005;75:9–17.CrossRefPubMed Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomized trial. Radiother Oncol. 2005;75:9–17.CrossRefPubMed
7.
go back to reference Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomize trial. Lancet Oncol. 2006;7:467–71.CrossRefPubMed Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomize trial. Lancet Oncol. 2006;7:467–71.CrossRefPubMed
8.
go back to reference Clark RM, Whelan T, Levine M, et al. Randomized clinical trial of breast irradiation following lumphectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst. 1996;88:1659–64.CrossRefPubMed Clark RM, Whelan T, Levine M, et al. Randomized clinical trial of breast irradiation following lumphectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst. 1996;88:1659–64.CrossRefPubMed
9.
go back to reference Olivotto IA, Weir LM, Kim-Sing C, et al. Late cosmetic results of short fractionation for breast conservation. Radiother Oncol. 1996;41:7–13.CrossRefPubMed Olivotto IA, Weir LM, Kim-Sing C, et al. Late cosmetic results of short fractionation for breast conservation. Radiother Oncol. 1996;41:7–13.CrossRefPubMed
10.
go back to reference Shelley W, Brundage M, Hayter C, Paszat L, Zhou S, Mackillop W. A shorter fractionation schedule for post lumpectomy breast cancer patients. Int J Radiat Oncol Biol Phys. 2000;47:1219–28.CrossRefPubMed Shelley W, Brundage M, Hayter C, Paszat L, Zhou S, Mackillop W. A shorter fractionation schedule for post lumpectomy breast cancer patients. Int J Radiat Oncol Biol Phys. 2000;47:1219–28.CrossRefPubMed
11.
go back to reference Fujii O, Hiratsuka J, Nagase N, et al. Whole breast radiotherapy with shorter fractionation schedules following breast-conserving surgery: short-term morbidity and preliminary outcomes. Breast Cancer. 2008;15:86–92.CrossRefPubMed Fujii O, Hiratsuka J, Nagase N, et al. Whole breast radiotherapy with shorter fractionation schedules following breast-conserving surgery: short-term morbidity and preliminary outcomes. Breast Cancer. 2008;15:86–92.CrossRefPubMed
12.
go back to reference Livi L, Stefanacci M, Scoccianti S, et al. Adjuvant hypofractionated radiation therapy for breast cancer after conserving surgery. R Coll Radiol. 2007;19:120–4.CrossRef Livi L, Stefanacci M, Scoccianti S, et al. Adjuvant hypofractionated radiation therapy for breast cancer after conserving surgery. R Coll Radiol. 2007;19:120–4.CrossRef
13.
go back to reference Zygogianni AG, Kouloulias V, Armpilia C, Balafouta M, Antypas C, Kouvaris JR. The potential role of hypofractionated accelerated radiotherapy to cosmesis for stage I-II breast carcinoma: a prospective study. J BUON. 2011;16:58–63.PubMed Zygogianni AG, Kouloulias V, Armpilia C, Balafouta M, Antypas C, Kouvaris JR. The potential role of hypofractionated accelerated radiotherapy to cosmesis for stage I-II breast carcinoma: a prospective study. J BUON. 2011;16:58–63.PubMed
14.
go back to reference Zygogianni AG, Kouvaris JR, Kouloulias V, Armpilia C, Antypas C, Vlachos L. Hypofractionated accelerated irradiation for stage I-II breast carcinoma: a phase II study. Breast J. 2010;16:337–8.CrossRefPubMed Zygogianni AG, Kouvaris JR, Kouloulias V, Armpilia C, Antypas C, Vlachos L. Hypofractionated accelerated irradiation for stage I-II breast carcinoma: a phase II study. Breast J. 2010;16:337–8.CrossRefPubMed
15.
go back to reference Whelan T, MacKenziew R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94:1143–50.CrossRefPubMed Whelan T, MacKenziew R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94:1143–50.CrossRefPubMed
16.
go back to reference Yarnold J, Bloomeld D, LeVay J. Prospective randomized trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in women with early breast cancer (FAST) trial. Clin Oncol. 2004;16:S30. Yarnold J, Bloomeld D, LeVay J. Prospective randomized trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in women with early breast cancer (FAST) trial. Clin Oncol. 2004;16:S30.
17.
go back to reference The START ‘Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet. 2008;29:1098–107. The START ‘Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet. 2008;29:1098–107.
18.
go back to reference The START ‘Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet. 2008;9:331–41.CrossRef The START ‘Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet. 2008;9:331–41.CrossRef
19.
go back to reference International Commission on Radiation Units and Measurements. Prescribing, recording and reporting photon beam therapy, ICRU report 50. Bethesda: International Commission on Radiation Units and Measurements; 1993. p. 3–16. International Commission on Radiation Units and Measurements. Prescribing, recording and reporting photon beam therapy, ICRU report 50. Bethesda: International Commission on Radiation Units and Measurements; 1993. p. 3–16.
20.
go back to reference International Commission on Radiation Units and Measurements. Prescribing, recording and reporting photon beam therapy, ICRU report 62. Bethesda: International Commission on Radiation Units and Measurements; 1999. International Commission on Radiation Units and Measurements. Prescribing, recording and reporting photon beam therapy, ICRU report 62. Bethesda: International Commission on Radiation Units and Measurements; 1999.
21.
go back to reference Wyatt M, Jones BJ, Dale RG. Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. Br J Radiol. 2008;81:549–63.CrossRefPubMed Wyatt M, Jones BJ, Dale RG. Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. Br J Radiol. 2008;81:549–63.CrossRefPubMed
22.
go back to reference Ramsey SD, Zeliadt SB, Richardson LC. Discontinuation of radiation treatment among Medicaid-enrolled women with local and regional stage breast cancer. Breast J. 2010;16:20–7.CrossRefPubMed Ramsey SD, Zeliadt SB, Richardson LC. Discontinuation of radiation treatment among Medicaid-enrolled women with local and regional stage breast cancer. Breast J. 2010;16:20–7.CrossRefPubMed
23.
go back to reference Sanpaolo P, Barbieri P, Genovesi D, Fusco V, Cefaro GA. Biologically effective dose and breast cancer conservative treatment: is duration of radiation therapy really important? Breast Cancer Res Treat. 2012;134:81–7.CrossRefPubMed Sanpaolo P, Barbieri P, Genovesi D, Fusco V, Cefaro GA. Biologically effective dose and breast cancer conservative treatment: is duration of radiation therapy really important? Breast Cancer Res Treat. 2012;134:81–7.CrossRefPubMed
24.
25.
go back to reference Thrapsanioti Z, Karanasiou I, Platoni K, et al. Transformation of physical DVHs to radiobiologically equivalent ones in hypofractionated radiotherapy analyzing dosimetric and clinical parameters: a practical approach for routine clinical practice in radiation oncology. Comput Math Methods Med. 2013;2013:713420. doi:10.1155/2013/713420.CrossRefPubMedPubMedCentral Thrapsanioti Z, Karanasiou I, Platoni K, et al. Transformation of physical DVHs to radiobiologically equivalent ones in hypofractionated radiotherapy analyzing dosimetric and clinical parameters: a practical approach for routine clinical practice in radiation oncology. Comput Math Methods Med. 2013;2013:713420. doi:10.​1155/​2013/​713420.CrossRefPubMedPubMedCentral
26.
go back to reference Bentzen S, Constine L, Deasy J, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An Introduction to the Scientific Issues. Int J Radiat Oncol Biol Phys. 2010;76(3):3–9.CrossRef Bentzen S, Constine L, Deasy J, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An Introduction to the Scientific Issues. Int J Radiat Oncol Biol Phys. 2010;76(3):3–9.CrossRef
27.
go back to reference Haustermans K, Fowler J, Geboes K, et al. Relationship between potential doubling time (Tpot), labeling index and duration of DNA synthesis in 60 esophageal and 35 breast tumors: is it worthwhile to measure Tpot? Radiother Oncol. 1998;46:157–67.CrossRefPubMed Haustermans K, Fowler J, Geboes K, et al. Relationship between potential doubling time (Tpot), labeling index and duration of DNA synthesis in 60 esophageal and 35 breast tumors: is it worthwhile to measure Tpot? Radiother Oncol. 1998;46:157–67.CrossRefPubMed
28.
go back to reference Clarke M, Collins R, Darby S, et al. Viewpoint: local Recurrence and 15 Year Survival in Early Breast Cancer: An Important Meta-analysis. Lancet. 2005;366:2087–106.CrossRefPubMed Clarke M, Collins R, Darby S, et al. Viewpoint: local Recurrence and 15 Year Survival in Early Breast Cancer: An Important Meta-analysis. Lancet. 2005;366:2087–106.CrossRefPubMed
29.
go back to reference Early Breast Cancer Trialists’ Collaborative Group. (EBCTCG). Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet. 2000;355:1757–70.CrossRef Early Breast Cancer Trialists’ Collaborative Group. (EBCTCG). Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet. 2000;355:1757–70.CrossRef
30.
go back to reference Armpilia C, Antypas C, Zygogianni A, et al. A review on radiotherapy hypofractionated schedules for breast cancer treatment. J Radiother pract. 2011;10:201–8.CrossRef Armpilia C, Antypas C, Zygogianni A, et al. A review on radiotherapy hypofractionated schedules for breast cancer treatment. J Radiother pract. 2011;10:201–8.CrossRef
31.
go back to reference Whelan TJ, Pignol J-P, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20.CrossRefPubMed Whelan TJ, Pignol J-P, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20.CrossRefPubMed
32.
go back to reference Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10 year follow-up results of two 17 randomized controlled trials. Lancet Oncol. 2013;14(11):1086–94.CrossRefPubMed Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10 year follow-up results of two 17 randomized controlled trials. Lancet Oncol. 2013;14(11):1086–94.CrossRefPubMed
33.
go back to reference Agrawal RK, Alhasso A, Barrett-Lee PJ, et al. First results of the 17randomized UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011;100(1):93e100. Agrawal RK, Alhasso A, Barrett-Lee PJ, et al. First results of the 17randomized UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011;100(1):93e100.
34.
go back to reference Coles CE, Brunt AM, Wheatley D, Mukesh MB, Yarnold JR. Breast radiotherapy: less is more? Clin Oncol. 2013;25(2):127–34.CrossRef Coles CE, Brunt AM, Wheatley D, Mukesh MB, Yarnold JR. Breast radiotherapy: less is more? Clin Oncol. 2013;25(2):127–34.CrossRef
35.
go back to reference Kirova YM, Campana F, Savignoni A, et al. Institut Curie Breast Cancer Study Group. Breast-conserving treatment in the elderly: long-term results of adjuvant hypofractionated and normofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2009;75(1):76–81.CrossRefPubMed Kirova YM, Campana F, Savignoni A, et al. Institut Curie Breast Cancer Study Group. Breast-conserving treatment in the elderly: long-term results of adjuvant hypofractionated and normofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2009;75(1):76–81.CrossRefPubMed
37.
go back to reference Donovan E, Bleakley N, Denholm E, et al. Breast Technology Group. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007;82(3):254–64.CrossRefPubMed Donovan E, Bleakley N, Denholm E, et al. Breast Technology Group. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007;82(3):254–64.CrossRefPubMed
Metadata
Title
A unique hypofractionated radiotherapy schedule with 51.3 Gy in 18 fractions three times per week for early breast cancer: outcomes including local control, acute and late skin toxicity
Authors
Kouloulias Vassilis
Gogalis Ioannis
Zygogianni Anna
Armpilia Christina
Antypas Christos
Kokakis John
Koromperlis Porfyrios
Gennimata Vassiliki
Kouvaris John
Publication date
01-03-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-016-0697-0

Other articles of this Issue 2/2017

Breast Cancer 2/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine